LTP·01learntopeptide
Metabolic & GLP-1PeptideEvidence B3 cited

Survodutide

GLP-1/Glucagon Dual Agonist

aka BI 456906 · BI456906 · dual GLP-1/glucagon agonist

A GLP-1 and glucagon dual agonist researched for weight loss and liver fat reduction.

Molecular wt
4232g/mol
Formula
C192H289N47O61
CAS
2805997-46-8
Half-life
4 days
clinical
Tmax
1 day
PubChem
171378821

Sequence

One-letter27 residues

HXQGTFTSDYSKYLDERAAKDFIKWLESA

Read this before quoting the sequence
29-residue acylated glucagon/GLP-1 receptor dual agonist (BI 456906). Sequence as recorded in ChEMBL (CHEMBL5314776, 'Sequence I'); 'X' at position 2 is a non-standard residue the record does not resolve. IUPHAR/BPS describes survodutide as 'an acylated peptide with a C18 fatty acid conjugate (mediates albumin binding), that in conjunction with removal of a dipeptidyl peptidase-4 proteolytic site, acts to extend its circulating half-life'. CAVEAT: the same ChEMBL record additionally lists a 'EGSGSGG' linker and an antibody light chain, which are inconsistent with the documented molecular formula C192H289N47O61 (MW 4232, roughly a 4.2 kDa peptide) and appear to be a database error; only 'Sequence I' is consistent with the chemistry and is reported here.
Source ↗

Mechanism of action

Survodutide works by activating both glucagon and GLP-1 receptors. This dual activation leads to reduced appetite and increased energy expenditure. The glucagon receptor activation promotes lipolysis and thermogenesis, while GLP-1 receptor activation enhances insulin secretion and satiety.

What the evidence actually shows

Grade B

There are a few human clinical trials that have shown Survodutide to be effective in reducing body weight and liver fat content in patients with obesity and NASH. However, long-term safety and efficacy data are still lacking, and more extensive trials are needed.

Regulatory status

Status
Investigational; not approved by FDA or EMA.
Clinical stage
Phase 3. ClinicalTrials.gov lists 9 Phase 3 studies (6 completed, 2 recruiting, 1 not yet recruiting) including the SYNCHRONIZE programme.
UK
emerging

Survodutide is currently considered an emerging compound in the UK, with ongoing clinical trials assessing its safety and efficacy.

Source ↗

Pharmacokinetics

Half-life
4 days
Tmax
1 day
Absorption
subcutaneous
Elimination
both
Washout
28 days
Titration
Dose escalation
Low-confidence pharmacokinetics
These figures are recorded as clinical rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Dosing — what backs each figure

Survodutide is an investigational glucagon/GLP-1 dual agonist with no approval; published human dosing is once-weekly subcutaneous with prolonged escalation (20-24 weeks) to maintenance targets of 3.6, 4.8 or 6.0 mg, given continuously for 46-76 weeks. Gastrointestinal adverse events were near-universal at the higher doses (89.7% at 6.0 mg in phase 3), which is why the escalation period is so long.

ClinicalApproved labelling or a published human trial

Handling and storage

No compound-specific stability data exists
No compound-specific stability data from an approved label or peer-reviewed stability study was located. Only generic research-peptide handling guidance exists, which is not compound-specific and is therefore not recorded here. Survodutide is investigational and has no approved label. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.
→ Reconstitution walkthrough→ Reconstitution calculator

Safety

Commonly reported
  • ·Nausea
  • ·Vomiting
  • ·Diarrhea
Rarely reported
  • ·Pancreatitis
  • ·"Thyroid tumors"
Contraindications
  • ·History of medullary thyroid carcinoma
  • ·Multiple endocrine neoplasia syndrome type 2
Drug interactions
  • ·Insulin: May enhance hypoglycemic effects

GI effects; heart-rate increase

Reported combinations

Reported as synergistic
  • ·Metformin
Reported as antagonistic
  • ·Corticosteroids: May counteract weight loss effects

Combination claims in this dataset are largely unsourced and should be treated as folk knowledge until a citation appears beside them.

References (3)

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
storage, reconstitution, regulatory.wada, sequence.position2Residue

Research use only
This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Metabolic & GLP-1

5-Amino-1MQ
A small molecule researched for blocking NNMT enzyme to boost NAD+ levels and fat metabolism.
Amycretin
Dual amylin/GLP-1 receptor agonist from Novo Nordisk. Single molecule.
AOD-9604
A modified hGH fragment researched for targeted fat breakdown without altering blood sugar or IGF-1.